IDEAYA Biosciences, Inc. reported its financial results for the first quarter ended March 31, 2025, on May 6, 2025. The company held approximately $1.05 billion in cash, cash equivalents, and marketable securities as of March 31, 2025.
IDEAYA updated its cash runway guidance, projecting that its current funds will be sufficient to fund planned operations into 2029. This extension is based on an updated operating plan with further pipeline prioritization.
Research and development (R&D) expenses for the quarter totaled $70.9 million, a decrease from the prior quarter primarily due to a one-time $75.0 million upfront payment for IDE849 in December 2024. The net loss for the quarter was $72.2 million. The company highlighted significant progress on darovasertib, including Breakthrough Therapy Designation, and advancements across its broad clinical pipeline, including IDE849, IDE275, and IDE397.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.